S88226 |
KU-60019 |
源叶(MedMol) | ≥98% |
- 产品描述: KU-60019是一种改进的KU-55933类似物,在无细胞试验中作用于ATM,IC50为6.3 nM,作用于ATM比作用于DNA-PK和ATR的选择性分别高270和1600倍,并且是高度有效的放射增敏剂
- 靶点: ATM(Cell-free assay):6.3 nM;ATM/ATR
- 体内研究:
In orthotopic glioma U1242/luc-GFP xenograft models, the combination of KU-60019 and radiation significantly increases survival of mice than KU-60019 alone, radiation alone, or no treatment. In addition, p53-mutant gliomas is much more sensitive to KU-60019 radiosensitization than wild-type glioma
- 细胞实验: Cell lines: U87和U1242 Concentrations: 溶于水,终浓度为~3 μM Incubation Time: 1, 3, 和5天 Method: 使用KU-60019处理细胞1, 3,和 5天。通过AlamarBlue测定细胞生长。AlamarBlue加到培养基中,达到推荐的最终浓度。实验板在37oC下温育1小时,在Fluoro-Count酶标仪上(激发光530 nm,发射光590 nm)测定荧光值, 测定结果昨晚衡量细胞生长的一个指标。通过台酚蓝/荧光激活的细胞分选(FACS)实验测定细胞存活。
- 动物实验: Animal Models: Athymic female mice harboring orthotopic glioma U1242/luc-GFP tumors or human glioma U1242/luc-GFP tumors Dosages: KU-60019 (10 μM) is delivered at a rate of 0.5 μL/h by osmotic pump; KU-60019 (250 μM) in 12.5 μL is infused by CED. Administration: Administered intratumorally by convection-enhanced delivery or osmotic pump
- 参考文献:
1. Golding SE, et al. Mol Cancer Ther, 2009, 8(10), 2894-2902. 2. Clin Cancer Res. 2013, 19(12), 3189-3200.
- 溶解性: Soluble in DMSO
- 保存条件: -20℃
- 配置溶液浓度参考:
1mg 5mg 10mg 1 mM 1.826 ml 9.129 ml 18.259 ml 5 mM 0.365 ml 1.826 ml 3.652 ml 10 mM 0.183 ml 0.913 ml 1.826 ml 50 mM 0.037 ml 0.183 ml 0.365 ml
- 注意:部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。
输入产品批号:
本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:
质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)